Начало・Списък с акции・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

9.02 2.5

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

8.75

Максимум

9.02

Ключови измерители
By Trading Economics
Приходи	-1.1B -722M
Продажби	-250M 156M
P/E Средно за сектора	7.603 68.51
EPS	0.14
Марж на печалбата	-461.478
Служители	435
EBITDA	-966M -700M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+148.47% upside

Дивиденти
By Acuity
Следващи печалби	5.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-99M 2.2B
Предишно отваряне	6.52
Предишно затваряне	9.02

BioCryst Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.08.2026 г., 19:36 ч. UTC

Correlated Moves

BioCryst Pharmaceuticals Inc shares are higher today, supported by gains in the biotechnology sector. The stock remains above its earlier low despite recent trends.

3.08.2026 г., 19:56 ч. UTC

BioCryst Pharmaceuticals Inc shares are lower today, continuing a downward trend since Friday. The broader market is seeing gains, contrasting with BioCryst's performance.

31.07.2026 г., 22:36 ч. UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market trading. No specific news was identified to explain this movement, reflecting routine performance since Friday's close.

30.07.2026 г., 20:09 ч. UTC

BioCryst Pharmaceuticals shares are lower amid broader market volatility following mixed economic signals, including rising jobless claims and disappointing GDP growth.

29.07.2026 г., 19:35 ч. UTC

BioCryst Pharmaceuticals Inc shares are lower amid a declining market, with no specific company news identified to explain the movement during today's session.

28.07.2026 г., 23:06 ч. UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market trading, continuing an upward trend from Tuesday's close, despite an earlier session pullback.

27.07.2026 г., 20:01 ч. UTC

BioCryst Pharmaceuticals Inc shares are trading higher in Monday's session, reflecting notable strength despite remaining near the lower end of their one-month trading range.

24.07.2026 г., 21:01 ч. UTC

BioCryst Pharmaceuticals Inc. shares are lower in after-market hours, reflecting broader market trends following a decline in the Nasdaq influenced by negative earnings reports.

22.07.2026 г., 21:51 ч. UTC

BioCryst Pharmaceuticals Inc shares are lower in after-market trading, continuing a decline amid significant volatility in U.S. markets and lack of specific news.

21.07.2026 г., 17:46 ч. UTC

BioCryst Pharmaceuticals Inc shares are higher today, continuing an upward trend since Monday. The stock remains below its 20-day moving average.

20.07.2026 г., 19:16 ч. UTC

Correlated Moves

Shares lower amid decline in Biotechnology sub-sector and SPDR ETF.

Сравнение с други в отрасъла

Ценова промяна

BioCryst Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

148.47% нагоре

12-месечна прогноза

Среден 21.89 USD 148.47%

Висок 32 USD

Нисък 12 USD

Според 9 анализатори от Wall Street, предложили 12-месечна ценова цел за BioCryst Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

9 ratings

Купи

Задържане

Продай

Според 9 анализатори, дали борсови рейтинги на BioCryst Pharmaceuticals Inc през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.